Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175600 | 0.90 | ANO1 (0.48) | KDM4EALDH1A1MAPTMEN1HPGD | |
| SCHEMBL4184629 | 0.87 | MAPT (0.53) | MAPTMEN1USP2POLBKMT2A | |
| SCHEMBL4180493 | 0.85 | ALDH1A1 (0.52) | KDM4EALDH1A1MAPTHPGDDRD2 | |
| SCHEMBL4190115 | 0.84 | HRH3 (0.52) | KDM4EALDH1A1MAPTPOLBHPGD | |
| SCHEMBL2825546 | 0.84 | WNT3A (0.52) | KDM4EALDH1A1MAPTMEN1POLB | |
| Cyclopentane SCHEMBL4947613 | 0.83 | HRH3 (0.46) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| Cyclohexane SCHEMBL4949278 | 0.83 | HRH3 (0.46) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| Cyclopropane SCHEMBL4950789 | 0.83 | HRH3 (0.46) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4949994 | 0.83 | HRH3 (0.46) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4177530 | 0.83 | MAPT (0.53) | KDM4EALDH1A1MAPTHPGDDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101080392-B | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE | 2010-05-05 | — | — | CN | claimed |
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | claimed |
| EP-1828134-B1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | EP | claimed |
| CN-101080392-A | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | claimed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | claimed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| CN-101080392-B | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE | 2010-05-05 | — | — | CN | disclosed |
| US-7612076-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | NETTEKOVEN MATTHIAS HEINRICH | 2009-02-12 | — | — | US | disclosed |
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1828134-B1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | EP | disclosed |
| CN-101080392-A | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HRH4, HRH3, H1-3 | KDM4E 541/4885ALDH1A1 814/4885MAPT 2843/4885 |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | HRH4, HRH3, H1-3 | KDM4E 541/4885ALDH1A1 814/4885MAPT 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.